Boehringer Ingelheim Office Hours
Boehringer Ingelheim Office Hours
Search
Boehringer Ingelheim Office Hours Video 2023
Video providing an overview of Boehringer Ingelheim’s Office Hours program and how its mentoring and access to expertise can help early-stage companies advance their science.
Office Hours Program | Partnering
Click here to find out how Boehringer Ingelheim's pioneering ‘Office Hours’ program has now mentored over 250 early-stage companies since 2015.
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies
New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Embracing Differences: Our journey to diversity, equity, and inclusion
Embracing Differences: Our journey to diversity, equity, and inclusion
Moving to Germany
We started in Germany, but we have offices all over the world.
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Corporate Compliance Program
Corporate Compliance Program
Occupational Health and Safety
Occupational Health and Safety
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
The View from Both Sides of the Table
The View from Both Sides of the Table
Helping pets in hurricane-ravaged Puerto Rico
Helping pets in hurricane-ravaged Puerto Rico
A Brave New World: Digital Health Redo | Boehringer Ingelheim US
Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.
Fighting Rabies in Madagascar | Boehringer Ingelheim US
Find out more about the Boehringer Ingelheim efforts to fight Rabies in Madagascar. Hear from a veterinarian who administered 75,000 vaccines to cats & dogs on the island.
Alexander Guntur
Alexander Guntur, Information Protection and Security officer in Singapore, describes his 14 years with the company as fulfilling.
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Recognizing Parents Supporting Other Parents
Recognizing Parents Supporting Other Parents
Anna Mistrioti
Anna Mistrioti speaks about working as a Quality Control Compliance Officer in Boehringer Ingelheim, in the Koropi Plant of Greece.
Lothar Halmer
Dr. Lothar Halmer is our Chief Quality Officer, and proud to have built a 25-year career with us.
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
Ridgefield, CT | BI Facilities
BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim
Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US
Find out more on the BI PROZINC® (protamine zinc recombinant human insulin) for most canine diabetics, a breakthrough for pet owners with diabetic dogs.